Overview
Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx
Status:
Completed
Completed
Trial end date:
2008-11-01
2008-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving docetaxel together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel together with radiation therapy works in treating patients with stage II or stage III cancer of the larynx or hypopharynx.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Aichi Cancer CenterTreatments:
Docetaxel
Criteria
DISEASE CHARACTERISTICS:- Histologically confirmed squamous cell carcinoma of the larynx or hypopharynx
- Stage II or III disease
- Solitary lymph node metastasis located in level II-III allowed
- Age 70 and over OR meets 1 of the following criteria:
- Creatinine clearance 30-60 mL/min
- History of platinum allergy
- Diagnosis of unstable angina
- Ineligible for systemic chemotherapy, including high-dose platinum-containing
regimens
PATIENT CHARACTERISTICS:
Age
- See Disease Characteristics
Performance status
- ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
- WBC > 3,000/mm^3
- Neutrophil count > 1,500/mm^3
- Hemoglobin > 10 g/dL
- Platelet count > 100,000/mm^3
Hepatic
- AST and ALT ≤ 2.0 times upper limit of normal
- Bilirubin < 2.0 mg/dL
- No severe liver disease
Renal
- See Disease Characteristics
- Creatinine clearance ≥ 30 mL/min
- No severe renal disease
Pulmonary
- No severe pulmonary disease
Other
- No severe neurologic disease
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior systemic chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- No prior radiotherapy
Surgery
- No prior surgery